Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 581 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04587739RecruitingPhase 1
Radiation before surgery for a single liver tumor
This early feasibility study tests a radiation plan given before surgery for hepatocellular carcinoma (a type of liver cancer) to see if it’s safe and doable. It may help shrink or control the tumor before an operation that aims to fully remove it.
LilleAges 18–70 - NCT06607107RecruitingPhase 2
Combination therapy for liver cancer beyond Milan criteria
This trial tests a combination of chemotherapy (mFOLFOX7) plus two targeted/immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer that has grown beyond standard transplant criteria. It aims to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07679061Recruiting
Nivolumab plus ipilimumab for liver cancer
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
Minato-ku, TokyoAges 18 years+ - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT06861114Recruiting
Urine test to detect liver cancer return after surgery
This study tests if a simple urine test can help find early signs of liver cancer coming back after surgery. Patients with early-stage liver cancer who have surgery may join to help improve follow-up care.
Guangzhou, GuangdongAges 18–75 - NCT07303712Recruiting
Liquid Biopsy for Liver Cancer After Y90 Treatment
This study uses a simple blood test (called a liquid biopsy) to learn more about your liver cancer after you receive a targeted radiation treatment called Y90 radioembolization. The goal is to see if the blood test can help doctors better understand how the cancer responds to treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT05828446Recruiting
Improving liver cancer screening for people at risk
This study looks at ways to improve screening for liver cancer in adults with long-term liver disease. It may help catch liver cancer earlier, which can make treatment easier.
Lausanne, Canton of VaudAges 18 years+ - NCT07122089RecruitingPhase 2
SIRT plus immunotherapy for liver cancer with portal vein clot
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
GrenobleAges 18 years+ - NCT06478719RecruitingPhase 1/Phase 2
FB-1603 plus TACE for liver cancer patients
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
Taipei, TaiwanAges 18–85 - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75 - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT06746194Recruiting
PET scan to check treatment response in advanced liver cancer
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07493668RecruitingPhase 2
Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT06788353Recruiting
Liver cancer treatment study for patients not eligible for surgery
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
Guangzhou, GuangdongAges 18–75 - NCT04348838Recruiting
Study of people newly diagnosed with liver cancer in France
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
AmiensAges 18 years+ - NCT06828380RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
GoyangAges 19 years+ - NCT06796114Recruiting
Biomarkers in advanced liver cancer treated with tremelimumab/durvalumab
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
BesançonAges 18 years+ - NCT06778317Recruiting
Blood test to predict liver cancer in cirrhosis patients
This trial tests if a simple blood test can help predict who with cirrhosis might develop liver cancer, so doctors can monitor and treat those patients earlier.
Vandœuvre-lès-NancyAges 18 years+ - NCT06644937RecruitingPhase 2/Phase 3
TACE with Icaritin after surgery for high-risk liver cancer
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
Guangzhou, GuangdongAges 18–75
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 581 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.